Insulet Stock Price, News & Analysis (NASDAQ:PODD) $194.54 +5.24 (+2.77%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$188.88▼$194.7550-Day Range$127.77▼$194.5452-Week Range$125.82▼$335.91Volume860,092 shsAverage Volume945,218 shsMarket Capitalization$13.58 billionP/E Ratio113.77Dividend YieldN/APrice Target$258.07 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Insulet MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside32.7% Upside$258.07 Price TargetShort InterestBearish7.69% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.75Based on 9 Articles This WeekInsider TradingSelling Shares$3.29 M Sold Last QuarterProj. Earnings Growth29.84%From $1.91 to $2.48 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.11 out of 5 starsMedical Sector17th out of 960 stocksSurgical & Medical Instruments Industry4th out of 75 stocks 4.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 12 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $258.07, Insulet has a forecasted upside of 32.7% from its current price of $194.54.Amount of Analyst CoverageInsulet has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.69% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 65.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 3.2 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Insulet this week, compared to 7 articles on an average week.Search InterestOnly 22 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat Follows9 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold 1,944,633.73% more of their company's stock than they have bought. Specifically, they have bought $169.00 in company stock and sold $3,286,600.00 in company stock.Percentage Held by InsidersOnly 0.80% of the stock of Insulet is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 29.84% in the coming year, from $1.91 to $2.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 113.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 113.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.37.Price to Earnings Growth RatioInsulet has a PEG Ratio of 2.57. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 28.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insulet Stock (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesNovember 9, 2023 | marketbeat.comWall Street sees these 2023 losers as 2024 opportunitiesAnalysts are pointing at undervalued, oversold companies like these three S&P 500 laggards as potential investment opportunities heading into 2024.November 8, 2023 | marketbeat.comLarge cap earnings trade ideas for risk-seeking investors (PODD)Positive earnings surprises (and the magnitude of surprises) are above historical norms as of late - and these three stocks could keep the party going.December 8, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Insulet (PODD) and AbbVie (ABBV)December 5, 2023 | americanbankingnews.comInsulet (NASDAQ:PODD) Upgraded to "Overweight" by Morgan StanleyDecember 4, 2023 | msn.comMorgan Stanley Upgrades Insulet (PODD)December 4, 2023 | finance.yahoo.comGM upgraded, Lululemon downgraded: Wall Street's top analyst callsNovember 30, 2023 | finance.yahoo.comSalesforce, Insulet, and Datadog Are November’s Top Performers—and These Are the WorstDecember 8, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 23, 2023 | finance.yahoo.comInsulet (PODD) Up 31.5% Since Q3 Earnings: What's Driving It?November 23, 2023 | msn.comIf You Invested $1000 in Insulet a Decade Ago, This is How Much It'd Be Worth NowNovember 15, 2023 | finance.yahoo.comPrestige Consumer's (PBH) Brand Building, Innovation Aid GrowthNovember 13, 2023 | finance.yahoo.comNovo Nordisk's Wegovy could reduce heart risks in new trialNovember 10, 2023 | finance.yahoo.com3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)November 8, 2023 | finance.yahoo.comSurging Earnings Estimates Signal Upside for Insulet (PODD) StockNovember 8, 2023 | finance.yahoo.comChemed's (CHE) VITAS Performance Aids, Macro Issues LingerNovember 7, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Baxter International (BAX), Alnylam Pharma (ALNY) and Insulet (PODD)November 7, 2023 | finance.yahoo.comInsulet (PODD) Banks on Omnipod for Consistent Market Share GainNovember 7, 2023 | finance.yahoo.comHere's How Much a $1000 Investment in Insulet Made 10 Years Ago Would Be Worth TodayNovember 6, 2023 | finance.yahoo.comInsulet (PODD) Just Overtook the 50-Day Moving AverageNovember 6, 2023 | finance.yahoo.comWall Street Analysts Think Insulet (PODD) Could Surge 53.28%: Read This Before Placing a BetNovember 6, 2023 | finance.yahoo.comInsulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View UpNovember 4, 2023 | benzinga.comBarron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock IncreaseNovember 4, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Insulet (PODD)November 4, 2023 | finance.yahoo.comThe Insulet Corp (PODD) Company: A Short SWOT AnalysisNovember 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Arcellx Inc (ACLX) and Insulet (PODD)November 3, 2023 | marketwatch.comInsulet Shares Rally After Company Boosts 2023 Revenue ViewSee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees2,600Year Founded2000Price Target and Rating Average Stock Price Target$258.07 High Stock Price Target$350.00 Low Stock Price Target$162.00 Potential Upside/Downside+32.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$1.71 Trailing P/E Ratio113.77 Forward P/E Ratio101.85 P/E Growth2.57Net Income$4.60 million Net Margins7.71% Pretax Margin8.29% Return on Equity23.98% Return on Assets5.46% Debt Debt-to-Equity Ratio2.26 Current Ratio3.26 Quick Ratio2.35 Sales & Book Value Annual Sales$1.56 billion Price / Sales8.72 Cash Flow$2.25 per share Price / Cash Flow86.50 Book Value$6.86 per share Price / Book28.36Miscellaneous Outstanding Shares69,828,000Free Float69,269,000Market Cap$13.58 billion OptionableOptionable Beta0.99 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 60)President, CEO & Director Comp: $2.18MMs. Shacey Petrovic (Age 49)Director & Advisor Comp: $2.96MMr. Eric Benjamin (Age 40)Executive VP, Chief Product & Customer Experience Officer Comp: $947.57kMs. Lauren BuddenGroup VP, Chief Accounting Officer, Controller & Interim CFO and TreasurerMr. Prem Singh (Age 46)Senior Vice President of Global Operations Mr. Mark FieldSenior VP & CTOMs. Deborah R. Gordon CPA (Age 53)Vice President of Investor Relations Mr. John Wodick Kapples (Age 63)Senior VP & General Counsel Comp: $783.36kMs. Laetitia Cousin (Age 47)Senior VP of Regulatory Affairs, Quality Assurance & Compliance Angela Geryak WiczekSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsTeleflexNYSE:TFXAbiomedNASDAQ:ABMDBaxter InternationalNYSE:BAXGlobus MedicalNYSE:GMEDResMedNYSE:RMDView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 27,500 shares on 12/7/2023Ownership: 0.039%Graham Capital Management L.P.Bought 20,171 shares on 11/22/2023Ownership: 0.033%Polar Capital Holdings PlcSold 5,500,000 shares on 11/22/2023Ownership: 0.027%Public Sector Pension Investment BoardBought 814 shares on 11/22/2023Ownership: 0.011%Walleye Trading LLCBought 4,000 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PODD Stock Analysis - Frequently Asked Questions Should I buy or sell Insulet stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price target for 2024? 17 brokerages have issued 12-month price objectives for Insulet's shares. Their PODD share price targets range from $162.00 to $350.00. On average, they predict the company's stock price to reach $258.07 in the next year. This suggests a possible upside of 32.7% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2023? Insulet's stock was trading at $294.39 on January 1st, 2023. Since then, PODD shares have decreased by 33.9% and is now trading at $194.54. View the best growth stocks for 2023 here. Are investors shorting Insulet? Insulet saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 5,370,000 shares, an increase of 65.7% from the October 31st total of 3,240,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the days-to-cover ratio is currently 3.6 days. View Insulet's Short Interest. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our PODD earnings forecast. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, November, 2nd. The medical instruments supplier reported $0.71 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.31. The medical instruments supplier had revenue of $432.70 million for the quarter, compared to analyst estimates of $413.82 million. Insulet had a trailing twelve-month return on equity of 23.98% and a net margin of 7.71%. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), Harbor Health Care ETF (MEDI), Fidelity Disruptive Medicine ETF (FMED), VictoryShares Nasdaq Next 50 ETF (QQQN) and Nuveen ESG Mid-Cap Growth ETF (NUMG). What guidance has Insulet issued on next quarter's earnings? Insulet updated its third quarter 2023 earnings guidance on Tuesday, October, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $402.14 million-$412.37 million, compared to the consensus revenue estimate of $414.30 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). Who are Insulet's major shareholders? Insulet's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Clearbridge Investments LLC (2.05%), William Blair Investment Management LLC (1.05%), Primecap Management Co. CA (0.98%), Northern Trust Corp (0.98%), Westfield Capital Management Co. LP (0.91%) and Bank of New York Mellon Corp (0.70%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PODD) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.